Tofacitinib May Have Possible Protective Effect Against ILD in RA

"Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk," said study first author Matthew C. Baker, MD.
Medscape Medical News

source https://www.medscape.com/viewarticle/989971?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost